ESMO Open : Impact Factor & More
eISSN: 2059-7029pISSN: 2059-7029
Open AccessShare this on:
Key Metrics
CiteScore 
6.6
Eigenfactor
0.005 - 0.01
Impact Factor
5 - 10
Scite Index
0.87 5-Year SI
SJR
Q2Oncology
SNIP
1.43
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on ESMO Open
ESMO Open Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | ELSEVIER |
| Language | English |
| Frequency | Bi-monthly |
| Article Processing Charges | EUR 3000 |
| Publication Time | 10 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | European Society for Medical Oncology |
| Frequency | Bi-monthly |
| Publication Start Year | 2016 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| License type | CC BY, CC BY-NC-ND |
| OA statement | Visit website |
View less
Planning to publish in ESMO Open ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in ESMO Open
ELECLA trial: final results of perioperative chemotherapy with fluoropyrimidine and oxaliplatin in mismatch repair proficient locally advanced colon cancer.
- 30 Jun 2026
- ESMO open
APOBEC mutational signatures predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.
- 30 Jun 2026
- ESMO open
Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.
- 30 Jun 2026
- ESMO open
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC).
- 22 Jun 2026
- ESMO open
ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers.
- 15 Jun 2026
- ESMO open
Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study.
- 12 Jun 2026
- ESMO open
ELECLA trial: final results of perioperative chemotherapy with fluoropyrimidine and oxaliplatin in mismatch repair proficient locally advanced colon cancer.
- 30 Jun 2026
- ESMO open
APOBEC mutational signatures predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.
- 30 Jun 2026
- ESMO open
Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.
- 30 Jun 2026
- ESMO open
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC).
- 22 Jun 2026
- ESMO open
ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers.
- 15 Jun 2026
- ESMO open
Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study.
- 12 Jun 2026
- ESMO open
FAQs on ESMO Open
How long has ESMO Open been actively publishing? 
What is the publishing frequency of ESMO Open?
How many articles did ESMO Open publish last year?
What is the eISSN & pISSN for ESMO Open?
What is Citescore for ESMO Open?
What is SNIP score for ESMO Open?
What is the SJR for ESMO Open?
Who is the publisher of ESMO Open?
